A Phase 4 interventional study of Carbidopa/levodopa/entacapone and Immediate release carbidopa/levodopa in Parkinson's Disease, sponsored by Novartis. Terminated at 21 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-02-18.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.
Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 18th largest by enrollment, is one of 5 that started in 2008, is one of 9 in phase 4, and was the 12th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
By country, each count listing its studies:
Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2004; this study’s year is marked. 5 started in 2008.
This study's enrollment of 14 is below the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 24 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 24 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
21 studies in Parkinson Disease by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 21 studies in Parkinson Disease by Novartis, this one is the 20th largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 4, and was the 11th registered.
Novartis’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing carbidopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Carbidopa/levodopa/entacapone
Drug: Immediate release carbidopa/levodopa
Drug pages: Carbidopa · Levodopa · Entacapone
Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
Also known as: Stalevo®
Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)
The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 4 non-motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the non-motor subscale of the QWOQ-9 is 0 to 16. A higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline to 15 minutes prior to 2nd dose at Week 8
Change From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)
The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 5 motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the motor subscale of the QWOQ-9 is 0 to 20. A higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline to 15 minutes prior to 2nd dose at Week 8
| Milestone | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa |
|---|---|---|
| Started | 7 | 7 |
| Completed | 5 | 4 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 4 non-motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the non-motor subscale of the QWOQ-9 is 0 to 16. A higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa |
|---|---|---|
| Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9) | -0.9 ± 0.90 | -0.2 ± 2.49 |
The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 5 motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the motor subscale of the QWOQ-9 is 0 to 20. A higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa |
|---|---|---|
| Change From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9) | -1.2 ± 2.23 | 0.0 ± 2.00 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carbidopa/Levodopa/Entacapone | — | 0/7 (0%) | 4/7 (57.1%) |
| Immediate Release Carbidopa/Levodopa | — | 0/7 (0%) | 1/7 (14.3%) |
| Event | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa |
|---|---|---|
| NauseaGastrointestinal disorders | 2/7 | 0/7 |
| NervousnessGeneral disorders | 1/7 | 0/7 |
| DyspepsiaGastrointestinal disorders | 1/7 | 0/7 |
| VomitingGastrointestinal disorders | 1/7 | 0/7 |
| FatigueGeneral disorders | 1/7 | 0/7 |
| OedemaGeneral disorders | 1/7 | 0/7 |
| Urinary tract infectionInfections and infestations | 1/7 | 0/7 |
| ExcoriationInjury, poisoning and procedural complications | 0/7 | 1/7 |
| FallInjury, poisoning and procedural complications | 1/7 | 1/7 |
| Head injuryInjury, poisoning and procedural complications | 0/7 | 1/7 |
| Age, Customized(Participants) | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 0 | 1 |
| >= 65 years | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Carbidopa/Levodopa/Entacapone | Immediate Release Carbidopa/Levodopa | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 2 | 5 | 7 |
The record gives a start of Mar 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone